DarioHealth Corp. (DRIO) - Dilution Analysis

10-Q filing | 6.6M shares outstanding

S-3 filing: The company may offer common stock, preferred stock, warrants to purchase common or preferred stock, and units in one or more offerings, for an aggregate initial offering amount of $100,000,000.

S-3/A filing: Consent to reference to the firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of DarioHealth Corp. for the registration of common stock.

10-Q filing | 6.8M shares outstanding

S-3 filing: The selling stockholders may offer from time to time up to 2,713,180 shares of common stock.

10-Q filing | 49.6M shares outstanding

S-3 filing: The selling stockholders may offer from time to time up to 8,772,489 shares of common stock.

S-3 filing: The filing relates to the resale by the selling stockholders identified in this prospectus of up to 52,139,659 shares of common stock.

10-Q filing | 47.4M shares outstanding

8-K filing: DarioHealth Corp. entered into a Credit Agreement and issued warrants to purchase 2,114,140 shares of common stock at an exercise price of $0.8278. Up to $2.5 million of the Term Loan can be converted into shares of common stock at a price of $0.9933 per share.

10-K filing | 38.4M shares outstanding

8-K filing: DarioHealth Corp. entered into securities purchase agreements for the sale of Series D-2 and Series D-3 Preferred Stock at $1,000 per share, resulting in gross proceeds of approximately $6,824,000. The closing will occur on or before January 14, 2025. ($6.82M proceeds)

8-K filing: DarioHealth Corp. entered into securities purchase agreements for the sale of Series D and Series D-1 Preferred Stock, resulting in gross proceeds of approximately $18.805 million, and amended its loan agreement with Avenue Venture Opportunities Fund. ($18.81M proceeds)

10-Q filing | 34.1M shares outstanding

10-Q filing | 30.0M shares outstanding

10-Q filing | 29.9M shares outstanding

S-3 filing: The filing relates to the resale by selling stockholders of up to 15,727,223 shares of common stock.

10-K filing | 28.4M shares outstanding

8-K filing: DarioHealth Corp. closed an offering on February 21, 2024, resulting in gross proceeds of approximately $22,422,000 from the sale of Series C, C-1, and C-2 Preferred Stock. ($22.42M proceeds)

8-K filing: DarioHealth Corp. acquired Twill, Inc. via merger, issuing cash, pre-funded warrants, stock options, and RSUs/warrants for DarioHealth shares. Also, DarioHealth closed a private placement offering of Series C, C-1, and C-2 Preferred Stock for gross proceeds of approximately $22.422 million. ($22.42M proceeds)

10-Q filing | 28.8M shares outstanding

10-Q filing | 28.2M shares outstanding

S-3 filing: The selling stockholders may offer from time to time up to 6,583,890 shares of common stock.

10-Q filing | 27.6M shares outstanding

8-K filing: DarioHealth Corp. entered into agreements for the sale of Series B Preferred Stock for gross proceeds of approximately $15.4 million, a Loan and Security Agreement for up to $40 million, and an agreement to issue up to 1,273,499 shares of Common Stock to holders of Series A-1 Convertible Preferred Stock in exchange for not converting their shares. ($15.4M proceeds)

10-K filing | 23.6M shares outstanding

S-3 filing: The selling stockholder may offer from time to time up to 107,409 shares of our common stock.

10-Q filing | 23.0M shares outstanding

10-Q filing | 22.4M shares outstanding

S-3 filing: The selling stockholder may offer from time to time up to 226,586 shares of our common stock upon the exercise of common stock purchase warrants issued on June 9, 2022.

8-K filing: DarioHealth Corp. entered into a Credit Agreement for a $50 million senior secured credit facility with OrbiMed, of which $25 million was available on June 9, 2022, and issued a warrant to OrbiMed to purchase up to 226,586 shares of common stock at an exercise price of $6.62 per share.

10-Q filing | 22.1M shares outstanding

10-K filing | 16.6M shares outstanding

8-K filing: Dario-Health Corp. entered into a Securities Purchase Agreement with institutional investors to issue and sell 4,674,454 shares of common stock and pre-funded warrants to purchase 667,559 shares at $7.49 and $7.4899 per share, respectively, for gross proceeds of approximately $40 million, in a registered direct offering expected to close on or about March 3, 2022. ($39.99M proceeds)

8-K filing: DarioHealth Corp. entered into a Technology Purchase Agreement with Physimax Technologies Ltd. to purchase Physimax Assets by issuing up to 256,660 shares of the Company's common stock at $21.35 per share, plus a cash payment of $500,000, and assuming approximately $1,020,000 in liabilities. ($5.5M proceeds)

10-Q filing | 16.5M shares outstanding

S-3 filing: The filing relates to a shelf offering of common stock with an aggregate initial offering amount of $200,000,000, and an at-the-market offering of common stock up to $50,000,000 through Cowen.

10-Q filing | 15.7M shares outstanding

8-K filing: DarioHealth Corp. entered into an agreement to acquire PsyInnovations, Inc., issuing up to $6.0 million in cash and up to $24.0 million in shares of common stock.

10-Q filing | 15.5M shares outstanding

S-3 filing: The selling stockholders may offer from time to time up to 3,278,688 shares of common stock.

10-K filing | 15.3M shares outstanding

8-K filing: DarioHealth Corp. acquired Upright Technologies Ltd. by issuing up to 1,800,000 shares of common stock and assuming/granting stock options, and also completed a private placement offering of 3,278,688 shares of common stock at $21.35 per share for gross proceeds of $70,000,000. ($70.0M proceeds)

10-Q filing | 8.1M shares outstanding

S-3 filing: The filing relates to the resale by selling stockholders of up to 3,825,441 shares of common stock purchased in a private placement offering that closed on July 31, 2020.

10-Q filing | 7.4M shares outstanding

8-K filing: DarioHealth Corp. completed an offering involving the sale of 2,969,266 shares of common stock at $7.47 per share and pre-funded warrants to purchase 824,689 shares at $7.4699 per warrant in a first closing on July 28, 2020, and the sale of 31,486 shares of common stock at $7.94 per share in a second closing on July 30, 2020.

10-Q filing | 3.8M shares outstanding

S-3/A filing: The selling stockholders may offer from time to time up to 4,652,126 shares of our common stock purchased in our private placement offering, which had multiple closings between November 27, 2019 and December 19, 2019.

8-K filing: DarioHealth Corp. issued a warrant to The Vitality Group, LLC to purchase up to 500,000 shares of its common stock at an exercise price of $5.94 per share, subject to vesting based on annual revenues from Vitality's customers.

S-3 filing: Resale by the selling stockholders identified in this prospectus of up to 4,652,126 shares of our common stock purchased in our private placement offering.

10-K filing | 3.1M shares outstanding